

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.*



## **INSIDE INFORMATION ANNOUNCEMENT AND RESUMPTION OF TRADING**

Reference is made to the announcement of China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 20 April 2022 in relation to trading halt of the Company’s shares (the “**Shares**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) pending release of an announcement in relation to inside information of the Company. This announcement is made by the Company pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on the Stock Exchange and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the “**SFO**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company has noted the recent unusual movements in the price and trading volume of the Shares. Having made such enquiry with respect to the Company as is reasonable in the circumstances, the Board confirms that the Company is currently in negotiation with independent third party(ies) regarding the potential acquisition of the commercialisation right of certain monoclonal antibody products (the “**Potential Acquisition**”), the potential disposal and relocation of certain manufacturing facilities of the Group (the “**Potential Disposal**”), and a potential strategic co-operation to develop new products of the Group (the “**Potential Co-operation**”, together with the Potential Acquisition and the Potential Disposal, the “**Potential Transactions**”).

As at the date of this announcement, negotiations are still ongoing. The Potential Transactions may or may not materialise. The terms and conditions regarding the Potential Transactions are yet to be finalised and no definitive agreement has been entered into by the Group regarding the Potential Transactions up to the date of this announcement. There is no assurance that the Potential Transactions will materialise or eventually be consummated. As such, the Potential Transactions may or may not proceed. Should the Potential Transactions materialise, they may constitute notifiable transactions under Chapter 14 of the Listing Rules. The Company will make further announcements in compliance with the Listing Rules as and when appropriate.

Save for as set out above, the Board is not aware of any reasons for such price and volume movements or of any information which must be announced to avoid a false market in the Company's securities or of any inside information that needs to be disclosed under the SFO.

## **RESUMPTION OF TRADING**

At the request of the Company, trading in the Shares was halted with effect from 11.15 a.m. on Wednesday, 20 April 2022. Application has been made by the Company to the Stock Exchange for the resumption of trading in the Shares with effect from 9.00 a.m. on Thursday, 21 April 2022.

**Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the Shares.**

By order of the Board  
**China NT Pharma Group Company Limited**  
**NG Tit**  
*Chairman*

Hong Kong, 20 April 2022

*As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Pan Fei and Dr. Zhao Yubiao.*